Drug-related problems among hospitalized patients with COPD in mainland China

被引:0
作者
Qin Li
Hui Jun Qu
Dan Lv
Ming-Kung Yeh
Shusen Sun
Ling Li
Yun Liao
机构
[1] Shanghai Jiao Tong University School of Medicine,Department of Pharmacy, Tongren Hospital
[2] Western New England University,Department of Pharmacy Practice, College of Pharmacy and Health Sciences
[3] Xiangya Hospital Central South University,Department of Pharmacy
[4] Central South University,Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital
来源
International Journal of Clinical Pharmacy | 2019年 / 41卷
关键词
China; Chronic obstructive pulmonary disease; Clinical pharmacy services; COPD; DRP; Drug-related problem;
D O I
暂无
中图分类号
学科分类号
摘要
Background Data are lacking about the extent of drug-related problems in hospitalized patients with COPD in China. Objective Identify types and causes of drug-related problems and assess interventions performed by pharmacists. Setting Study was conducted in an academic teaching hospital in Shanghai, China. Method Between June 2017 and July 2018, 393 patients admitted to hospital for acute exacerbation of COPD hospitalized were enrolled. Patient demographics and clinical characteristics were collected. The drug-related problems and interventions were recorded and analyzed based on the Pharmaceutical Care Network Europe (PCNE)-DRP V 8.02 classification. Main outcome measures The number, types, causes, interventions, and outcomes of the problems were analyzed. Results A total of 640 DRPs, with 763 corresponding causes, were identified for 393 patients. “Treatment safety P2” was the most common type of problem (54.2%; 347/640), and the most common causes were “drug selection C1” (24.2%; 185/763), “dose selection C3” (21.5%; 164/763) and “treatment duration C4” (17.7%; 135/763). Antibiotics, corticosteroids, and proton pump inhibitors were the three primary medication classes associated with DRPs. Patients, hospitalized for more than eight days, taking ten or more drugs or having renal dysfunctions were more likely to have drug-related problems. Pharmacists totally proposed 1557 interventions to address the problems. Most interventions (91.0%; 1418/1557) were accepted, and 91.6% of the problems were solved. Conclusion The prevalence of drug-related problems among the studied COPD patients was high. Pharmacists can have an important role in addressing the problems and optimizing the safety and effectiveness of therapies for hospitalized COPD patients.
引用
收藏
页码:1507 / 1515
页数:8
相关论文
共 140 条
  • [1] Vogelmeier CF(2017)Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary Eur Respir J 49 1700214-1454
  • [2] Criner GJ(2013)Preventing acute exacerbations and hospital admissions in COPD Chest 143 1444-929
  • [3] Martinez FJ(2011)COPD in China: the burden and importance of proper management Chest 139 920-1280
  • [4] Anzueto A(2016)A subnational analysis of mortality and prevalence of COPD in China from 1990 to 2013: findings from the global burden of disease study 2013 Chest 150 1269-150
  • [5] Barnes PJ(2015)Economic burden of COPD in the presence of comorbidities Chest 148 138-457
  • [6] Bourbeau J(2014)Predictors of the overlap syndrome and its association with comorbidities in patients with chronic obstructive pulmonary disease Respiration 88 451-776
  • [7] Marchetti N(2008)Drug-related problems: evaluation of a classification system in the daily practice of a Swiss University Hospital Pharm World Sci 30 768-1151
  • [8] Criner GJ(2013)Clinical pharmacist service in the acute ward Int J Clin Pharm 35 1137-416
  • [9] Albert RK(2013)A systematic review of the clinical and economic effectiveness of clinical pharmacist intervention in secondary prevention of cardiovascular disease J Manag Care Pharm 19 408-62
  • [10] Fang X(2012)Impact of pharmaceutical care on health outcomes in patients with COPD Int J Clin Pharm 34 53-344